首頁 > 市場調查報告書 > 製藥

糖尿病

市場調查報告書

商品編碼

1561616

2024-2032 年按產品、適應症、配銷通路和地區分類的速效胰島素市場報告

Rapid Acting Insulin Market Report by Product, Indication, Distribution Channel, and Region 2024-2032

出版日期: 2024年09月10日 | 出版商:

IMARC | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

2023年，全球IMARC Group胰島素市場規模達77億美元。患者的嚴重程度和死亡風險不斷增加、大眾對個人化醫療的日益關注以及研發（R＆D）活動投資的增加是推動市場的一些主要因素。

速效胰島素是一種用於治療糖尿病的胰島素，特別是用於控制餐後血糖高峰。它旨在模仿人體進食後的自然胰島素反應，注射後 15 分鐘內起效。這種迅速的作用有助於有效控制血糖水平，因為它可以調節人體的葡萄糖代謝。速效胰島素在給藥後一到兩個小時左右發揮作用高峰，使其能夠在這段關鍵時期有效降低高血糖水平。它允許糖尿病患者根據膳食消耗來安排注射時間，從而提供更個人化的治療方法。它可以增強糖尿病管理，為患者提供更好的生活品質，並降低與血糖水平失控相關的併發症風險。

速效胰島素市場趨勢/促進因素：

大眾中糖尿病盛行率不斷上升

全世界糖尿病的發生率正以驚人的速度上升。久坐的生活方式、不健康的飲食習慣和肥胖是導致糖尿病發生率上升的一些關鍵因素。隨著越來越多的人被診斷出患有糖尿病，對有效且速效胰島素的需求持續成長。速效胰島素在控制餐後血糖高峰方面發揮著至關重要的作用，為患者提供更快、更有效的控制血糖水平的方法。醫療保健提供者擴大開出速效胰島素來滿足餐後即時的胰島素需求，從而降低高血糖和相關併發症的風險。隨著糖尿病人口的增加，製藥公司正在加大研發投入，以改善速效胰島素配方，提高其功效並為患者提供便利。

持續的技術進步

醫療技術的創新徹底改變了胰島素輸送系統，使其更加方便用戶使用和準確。胰島素筆、胰島素幫浦和連續血糖監測 (CGM) 設備在糖尿病患者中越來越受歡迎，有助於更輕鬆地管理和精確劑量的胰島素。速效胰島素製劑旨在與這些現代輸送系統完美配合，進一步滿足他們的需求。胰島素筆提供謹慎且方便的胰島素輸送，而胰島素幫浦則根據個人需求提供連續且個人化的胰島素輸注。這些技術創新改善了血糖控制，降低了低血糖發作的風險，並提高了患者的整體生活品質。因此，速效胰島素與這些先進設備的兼容性已成為市場成長的重要動力。

提高意識和醫療基礎設施

人們對糖尿病及其管理的認知不斷提高，加上醫療基礎設施的擴大，大大增加了對速效胰島素的需求。糖尿病意識活動、教育舉措和篩檢計畫促進了患者的早期診斷和及時干預，增加了尋求適當治療的人數。醫生和醫療保健專業人員擴大開出速效胰島素，以幫助患者更好地控制餐後血糖，並預防高血糖發作和長期併發症。此外，政府和醫療保健組織正在投資糖尿病管理計劃，改善獲得基本藥物的機會，包括速效胰島素。意識的提高、醫療設施的改善以及糖尿病治療負擔能力的提高，為速效胰島素市場的擴張創造了有利的環境。

The global rapid acting insulin market size reached US$ 7.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.2 Billion by 2032, exhibiting a growth rate (CAGR) of 4.1% during 2024-2032. The increasing risks of severity and mortality among patients, the growing focus on personalized medicine among the masses, and the increasing investments in research and development (R&D) activities are some of the major factors propelling the market.

A rapid-acting insulin is a type of insulin used in the treatment of diabetes, specifically for managing post-meal blood sugar spikes. It is designed to mimic the body's natural insulin response after eating, with an onset of action within 15 minutes of injection. This swift action helps to control blood sugar levels effectively, as it works to regulate the body's metabolism of glucose. Rapid-acting insulin peaks in its effect around one to two hours after administration, enabling it to efficiently lower high blood sugar levels during this critical period. It allows individuals with diabetes to time their injections in correlation with meal consumption, providing a more personalized treatment approach. It enhances diabetes management, providing patients with a better quality of life and reducing the risk of complications associated with uncontrolled blood sugar levels.

Rapid Acting Insulin Market Trends/Drivers:

The Increasing Prevalence of Diabetes Among the Masses

The incidences of diabetes have been escalating at an alarming rate worldwide. Sedentary lifestyles, unhealthy dietary habits, and obesity are some of the key factors contributing to the rising incidence of diabetes. As more individuals are diagnosed with diabetes, the demand for effective and rapid-acting insulin continues to grow. Rapid-acting insulin plays a crucial role in managing post-meal blood sugar spikes, providing patients with a faster and more efficient way to control their glucose levels. Healthcare providers increasingly prescribe rapid-acting insulin to address the immediate insulin needs after meals, reducing the risk of hyperglycemia and associated complications. As the diabetic population expands, pharmaceutical companies are investing more in research and development to improve rapid-acting insulin formulations, enhancing their efficacy and convenience for patients.

Continual Technological Advancements

Innovations in medical technology have revolutionized insulin delivery systems, making them more user-friendly and accurate. Insulin pens, insulin pumps, and continuous glucose monitoring (CGM) devices have become increasingly popular among diabetes patients, facilitating easier administration and precise dosing of insulin. Rapid-acting insulin formulations are designed to work optimally with these modern delivery systems, further fueling their demand. Insulin pens offer discreet and convenient insulin delivery, while insulin pumps provide a continuous and personalized insulin infusion based on individual needs. These technological innovations have improved glycemic control, reduced the risk of hypoglycemic episodes, and enhanced patient's overall quality of life. As a result, the compatibility of rapid-acting insulin with these advanced devices has become a significant driving force behind the market's growth.

Increasing Awareness and Healthcare Infrastructure

Growing awareness about diabetes and its management, coupled with the expansion of healthcare infrastructure, has significantly contributed to the demand for rapid-acting insulin. Diabetes awareness campaigns, educational initiatives, and screening programs have led to early diagnosis and timely intervention for patients, increasing the number of individuals seeking appropriate treatment. Physicians and healthcare professionals are increasingly prescribing rapid-acting insulin to help patients achieve better post-prandial glucose control, preventing hyperglycemic episodes and long-term complications. Moreover, governments and healthcare organizations are investing in diabetes management programs, improving access to essential medications, including rapid-acting insulin. The combination of heightened awareness, better healthcare facilities, and increased affordability of diabetes treatment has created a favorable environment for the rapid-acting insulin market's expansion.

Rapid Acting Insulin Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global rapid acting insulin market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product, indication and distribution channel.

Breakup by Product:

Lispro Insulin
Aspart Insulin
Glulisine Insulin

Lispro insulin dominates the market

The report has provided a detailed breakup and analysis of the market based on the product. This includes lispro insulin, aspart insulin and glulisine insulin. According to the report, lispro insulin represented the largest segment.

Lispro insulin's popularity can be attributed to its fast onset of action, typically within a few minutes after administration, which helps control post-meal blood sugar spikes more effectively. This rapid action allows individuals with diabetes to time their insulin injections closer to meal consumption, providing greater flexibility and convenience in managing their blood glucose levels. Moreover, Lispro insulin is compatible with various insulin delivery devices, such as insulin pens and insulin pumps, further enhancing its ease of use and patient compliance. Apart from this, numerous physicians and healthcare providers frequently prescribe Lispro insulin due to its proven efficacy and safety profile. It has demonstrated its effectiveness in managing both type 1 and type 2 diabetes, making it a versatile option for a wide range of patients.

Breakup by Indication:

Type 1 Diabetes
Type 2 Diabetes

Type 2 diabetes hold the largest share in the market

A detailed breakup and analysis of the market based on the indication has also been provided in the report. This includes type 1 diabetes and type 2 diabetes. According to the report, type 2 diabetes accounted for the largest market share.

Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance and impaired glucose regulation, leading to elevated blood sugar levels. Rapid-acting insulin plays a crucial role in the management of type 2 diabetes, particularly in addressing post-meal hyperglycemia. After a meal, individuals often experience a rapid increase in blood sugar levels, which can contribute to various health complications if left uncontrolled. As awareness about diabetes and its management continues to rise, coupled with the efforts to improve access to healthcare and diabetes care, the demand for rapid-acting insulin is expected to remain significant, solidifying its prominent position in the market. The increasing prevalence of type 2 diabetes, driven by factors like sedentary lifestyles, obesity, and an aging population, has resulted in a growing patient pool seeking diabetes management solutions.

Breakup by Distribution Channel:

Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Stores

Drug stores and retail pharmacies hold the largest share in the market

A detailed breakup and analysis of the market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, drug stores and retail pharmacies and online stores. According to the report, drug stores and retail pharmacies accounted for the largest market share.

Drug stores and retail pharmacies are widespread and easily accessible, making them convenient points of purchase for patients seeking their diabetes medications. This accessibility ensures that patients can promptly refill their prescriptions and access essential rapid-acting insulin whenever needed, promoting better adherence to treatment regimens and overall diabetes management. Moreover, drug stores and retail pharmacies offer a diverse range of rapid-acting insulin products, providing patients with multiple options to choose from based on their specific needs and preferences. Pharmacists at these locations also play a vital role in patient education, helping individuals understand proper insulin administration, potential side effects, and the importance of medication adherence. Additionally, drug stores and retail pharmacies often participate in health insurance plans, which further facilitates access to rapid-acting insulin for patients, potentially reducing the financial burden associated with diabetes management.

Breakup by Region:

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

North America exhibits a clear dominance, accounting for the largest rapid acting insulin market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America boasts a high prevalence of diabetes, with both the United States and Canada experiencing an alarming increase in diabetes cases over the years. The region has a well-established healthcare infrastructure that emphasizes diabetes management and treatment. Access to advanced medical technologies, insulin delivery devices, and continuous glucose monitoring systems has enhanced patient care and contributed to the widespread adoption of rapid-acting insulin therapies. Moreover, North America is at the forefront of research and development in the pharmaceutical industry, leading to the introduction of innovative and effective rapid-acting insulin formulations. This continuous focus on advancements ensures that the region remains a key player in shaping the future of diabetes treatment. Furthermore, robust healthcare policies and insurance coverage in North America facilitate easier access to diabetes medications, including rapid-acting insulin, for a large portion of the population. This accessibility has significantly contributed to the region's dominant market share.

Competitive Landscape:

Pharmaceutical companies are investing heavily in R&D to discover and develop innovative rapid-acting insulin formulations. They aim to improve the pharmacokinetics, onset of action, and duration of these insulins to better meet the needs of patients. Additionally, companies are exploring new insulin delivery systems, such as ultra-rapid-acting insulins, oral insulin formulations, and inhalable insulin, to enhance convenience and patient compliance. Moreover, companies are pursuing regulatory approvals from health authorities in various countries to expand the market reach of their rapid-acting insulin products. Furthermore, leading players are focusing on expanding their presence in emerging economies with a high prevalence of diabetes. By increasing access to rapid-acting insulin in these regions, they can tap into untapped market potential and improve diabetes management globally. Additionally, pharmaceutical companies are actively involved in patient education and support programs to raise awareness about diabetes management and the importance of insulin therapy.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Adocia
Biocon Limited
Eli Lilly and Company
Gan & Lee Pharmaceuticals Co. Ltd.
Geropharm
MannKind Corporation
Merck & Co. Inc.
Novo Nordisk A/S
Sanofi S.A.
Wockhardt Ltd.

Recent Developments:

In November 2022, Biocon Limited Completes Acquisition of Viatris' Global Biosimilars Business. The acquisition provides Biocon Biologics with direct commercial capabilities and supporting infrastructure in the advanced markets and several emerging markets, bringing it closer to patients, customers, and payors.
In July 2022, Merck & Co. Inc. announces its collaboration with Orion, Global Collaboration for the Development and Commercialization of ODM-208, an investigational steroid synthesis inhibitor for the treatment of metastatic castration-resistant prostate cancer.
In May 2022, MannKind Corporation Announces Agreement to Acquire V-Go(R) Insulin Delivery Device from Zealand Pharma. The acquisition of V-Go allows MannKind to expand its portfolio and strengthen its commitment to providing innovative mealtime diabetes solutions.

Key Questions Answered in This Report:

How has the global rapid acting insulin market performed so far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global rapid acting insulin market?
What is the impact of each driver, restraint, and opportunity on the global rapid acting insulin market?
What are the key regional markets?
Which countries represent the most attractive rapid acting insulin market?
What is the breakup of the market based on the product?
Which is the most attractive product in the rapid acting insulin market?
What is the breakup of the market based on the indication?
Which is the most attractive indication in the rapid acting insulin market?
What is the breakup of the market based on the distribution channel?
Which is the most attractive distribution channel in the rapid acting insulin market?
What is the competitive structure of the global rapid acting insulin market?
Who are the key players/companies in the global rapid acting insulin market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Rapid Acting Insulin Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product

6.1 Lispro Insulin
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Aspart Insulin
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Glulisine Insulin
- 6.3.1 Market Trends
- 6.3.2 Market Forecast

7 Market Breakup by Indication

7.1 Type 1 Diabetes
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Type 2 Diabetes
- 7.2.1 Market Trends
- 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

8.1 Hospital Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Drug Stores and Retail Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Online Stores
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 Adocia
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
  - 14.3.1.3 Financials
- 14.3.2 Biocon Limited
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
  - 14.3.2.3 Financials
  - 14.3.2.4 SWOT Analysis
- 14.3.3 Eli Lilly and Company
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
  - 14.3.3.3 Financials
  - 14.3.3.4 SWOT Analysis
- 14.3.4 Gan & Lee Pharmaceuticals Co. Ltd.
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
  - 14.3.4.3 Financials
- 14.3.5 Geropharm
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
- 14.3.6 MannKind Corporation
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
  - 14.3.6.3 Financials
  - 14.3.6.4 SWOT Analysis
- 14.3.7 Merck & Co. Inc.
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
  - 14.3.7.3 Financials
  - 14.3.7.4 SWOT Analysis
- 14.3.8 Novo Nordisk A/S
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
  - 14.3.8.3 Financials
  - 14.3.8.4 SWOT Analysis
- 14.3.9 Sanofi S.A.
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
  - 14.3.9.3 Financials
  - 14.3.9.4 SWOT Analysis
- 14.3.10 Wockhardt Ltd.
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio
  - 14.3.10.3 Financials

簡介目錄圖表

List of Figures

Figure 1: Global: Rapid Acting Insulin Market: Major Drivers and Challenges
Figure 2: Global: Rapid Acting Insulin Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Rapid Acting Insulin Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Rapid Acting Insulin Market: Breakup by Product (in %), 2023
Figure 5: Global: Rapid Acting Insulin Market: Breakup by Indication (in %), 2023
Figure 6: Global: Rapid Acting Insulin Market: Breakup by Distribution Channel (in %), 2023
Figure 7: Global: Rapid Acting Insulin Market: Breakup by Region (in %), 2023
Figure 8: Global: Rapid Acting Insulin (Lispro Insulin) Market: Sales Value (in Million US$), 2018 & 2023
Figure 9: Global: Rapid Acting Insulin (Lispro Insulin) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 10: Global: Rapid Acting Insulin (Aspart Insulin) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Rapid Acting Insulin (Aspart Insulin) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Rapid Acting Insulin (Glulisine Insulin) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Rapid Acting Insulin (Glulisine Insulin) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Rapid Acting Insulin (Type 1 Diabetes) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Rapid Acting Insulin (Type 1 Diabetes) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Rapid Acting Insulin (Type 2 Diabetes) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Rapid Acting Insulin (Type 2 Diabetes) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Rapid Acting Insulin (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Rapid Acting Insulin (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Rapid Acting Insulin (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Rapid Acting Insulin (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Rapid Acting Insulin (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Rapid Acting Insulin (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: North America: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: North America: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: United States: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: United States: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Canada: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Canada: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Asia-Pacific: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Asia-Pacific: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: China: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: China: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: Japan: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: Japan: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: India: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: India: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: South Korea: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: South Korea: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: Australia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: Australia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: Indonesia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: Indonesia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Europe: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Europe: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: Germany: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: Germany: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: France: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: France: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: United Kingdom: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: United Kingdom: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: Italy: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: Italy: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: Spain: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: Spain: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: Russia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: Russia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: Latin America: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: Latin America: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Brazil: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Brazil: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Mexico: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Mexico: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: Middle East and Africa: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: Middle East and Africa: Rapid Acting Insulin Market: Breakup by Country (in %), 2023
Figure 72: Middle East and Africa: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 73: Global: Rapid Acting Insulin Industry: SWOT Analysis
Figure 74: Global: Rapid Acting Insulin Industry: Value Chain Analysis
Figure 75: Global: Rapid Acting Insulin Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Rapid Acting Insulin Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Rapid Acting Insulin Market Forecast: Breakup by Product (in Million US$), 2024-2032
Table 3: Global: Rapid Acting Insulin Market Forecast: Breakup by Indication (in Million US$), 2024-2032
Table 4: Global: Rapid Acting Insulin Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
Table 5: Global: Rapid Acting Insulin Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 6: Global: Rapid Acting Insulin Market: Competitive Structure
Table 7: Global: Rapid Acting Insulin Market: Key Players

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

速效型胰島素的全球市場的預測:各產品，各適應症，各流通管道，各國，企業的分析

FAQ

2024-2032 年按產品、適應症、配銷通路和地區分類的速效胰島素市場報告

Rapid Acting Insulin Market Report by Product, Indication, Distribution Channel, and Region 2024-2032

速效胰島素市場趨勢/促進因素：

目錄

第1章：前言

第 2 章：範圍與方法

第 3 章：執行摘要

第 4 章：簡介

第 5 章：全球速效胰島素市場

第 6 章：市場區隔：依產品

第 7 章：市場區隔：依跡象

第 8 章：市場區隔：按配銷通路

第 9 章：市場區隔：按地區

第 10 章：SWOT 分析

第 11 章：價值鏈分析

第 12 章：波特五力分析

第 13 章：價格分析

第14章：競爭格局